Chardan Healthcare Conference – 10 Years of Disruptive Innovation - SAB BIOTHERAPEUTICS INC

Based on the transcript provided, here is the extraction and summary of forward-looking statements. Note that the transcript is an analyst discussion containing no explicit financial guidance (revenue, earnings, margins, etc.) or macroeconomic outlooks. The forward-looking content is strictly limited to operational milestones, regulatory pathways, and clinical study timelines.

• Explicit Guidance:

  • None. The transcript contains no specific numerical financial guidance (revenue, earnings, capex, or cash flow) or share count/dividend updates.

• Business-Segment Outlook:

  • Helios (SABbio) – ARDS (Japan):
    • Commercialization: Aiming for conditional approval and launch in Japan for Acute Respiratory Distress Syndrome (ARDS).
    • Manufacturing Scale: Transitioning to a commercial facility in Kobe, Japan, utilizing 500-liter bioreactors.
    • Capacity: The 500-liter facility is designed to produce 40,000 doses annually; a 50-liter suite (currently in Yokohama) produces ~1,000 doses/year (scalable to 5,000).
    • Cost of Goods (COGS): Projected to drop by two-thirds or more when scaling from 50L to 500L bioreactors.
    • Timeline: Filing expected "in the coming months" post-manufacturing runs; approval timeline estimated at 9 months post-filing (conditional for orphan drug).
  • SABbio – Type 1 Diabetes (ATG Platform):
    • Regulatory Strategy: Aiming for full approval (not just accelerated) by demonstrating preservation of C-peptide and reduction in HbA1c (clinical endpoint), following precedent set by the recent approval of T-Zield on C-peptide alone.
    • Target Population Expansion: Potential to expand the labeled population from "within 100 days of diagnosis" to "up to 2 years post-diagnosis" if the Phase 3 PRIZE study validates C-peptide preservation as the primary driver of efficacy regardless of time from diagnosis.

• Market and Competitive Outlook:

  • Japan Market: Positioned as the global leader in cell therapy regulatory approval and commercialization, offering a faster, lower-cost manufacturing path compared to the U.S. due to favorable industrial policy, government funding, and lower labor costs (approx. 1/3 the cost of Singapore/US manufacturing).
  • Competitive Landscape (Diabetes):
    • Current Standard: Rabbit anti-thymocyte globulin (Thymoglobulin) is efficacious but cannot be redosed due to serum sickness; Sanofi has deprioritized it for T1D.
    • Competitor Move: T-Zield recently received accelerated approval based on C-peptide, validating C-peptide as a sufficient surrogate endpoint for accelerated approval but necessitating post-marketing clinical proof.
    • Differentiation: SABbio's humanized ATG (from cows) aims to replicate the efficacy of Thymoglobulin but with the safety profile and redosing capability required for a chronic condition like T1D.

• Macro / Industry Outlook:

  • Regulatory Environment:
    • Japan: Described as "highly cell therapy favorable" with established paths for accelerated approvals and government grants (e.g., $50M for the 500L facility).
    • US/FDA: Confirmed that C-peptide is sufficient for accelerated approval for diabetes, but full approval requires clinical endpoints (HbA1c).
  • Cost Environment: Note on Japan's low inflation and weak dollar providing a significant cost arbitrage for manufacturing compared to the US.

• Strategic Initiatives:

  • Helios Manufacturing Expansion:
    • Timeline: Moving from Singapore (Lonza) to Japan (Monaris in Yokohama, then Kobe) is complete/in progress.
    • Action: Currently running process characterization and data generation for the Japan filing.
  • Clinical Development (Global):
    • Helios: Initiating a global Phase 3 study for ARDS (pneumonia-induced) across ~80 sites globally, heavily weighted toward the US, with sites in Europe, Korea, Taiwan, Australia, and potential sites in China.
    • SABbio (Safeguard Study): Phase IIb (Registrational) study enrolling 159 newly diagnosed T1D patients (ages 5–40) across three cohorts; enrollment "near completion."
    • SABbio (PRIZE Study): Phase 3 study initiated by Dr. Haller to test efficacy in patients diagnosed 100 days to 2 years post-diagnosis to expand the addressable market.
  • M&A Integration: Helios acquired Atherosys assets (cell therapy platform) for $2.25M in early 2024 after the original developer went bankrupt.

• Risks and Headwinds to Outlook:

  • Regulatory Risk: While Japan offers a favorable path, the company notes the ultimate market focus remains the US; success in Japan does not guarantee US approval without successful global Phase 3 data.
  • Manufacturing Complexity: Scaling bioreactors (50L to 500L) and maintaining consistent potency assays (advanced class) are critical mission-critical hurdles.
  • Study Outcomes:
    • Helios: Reliance on "filing" progress; failure to complete characterization data delays the 9-month approval window.
    • SABbio: Reliance on the PRIZE study proving C-peptide efficacy is time-independent; failure to show benefit in the 1–2 year cohort could limit market size.
    • Clinical Endpoints: For full FDA approval, SABbio must demonstrate HbA1c reduction in the Safeguard study, not just C-peptide preservation.

• Management Tone on the Future:

  • Confidence Level: High on manufacturing readiness (Helios) and de-risked clinical strategy (SABbio).
  • Helios: "Counting our blessings" regarding the acquisition cost vs. value inherited; confident in the speed of the Japanese regulatory path.
  • SABbio: Describes the approach as "highly de-risked" because it replicates the mechanism of a proven drug (Thymoglobulin) while solving the redosing/safety flaw.
  • General Tone: Optimistic about the "inflection points" of approval and commercialization, specifically targeting 2027 for Helios ARDS approval and 2026 for SABbio clinical data.

• Miscellaneous:

  • Timeline Summary:
    • 2026: Key clinical data expected from SABbio's Safeguard and PRIZE studies.
    • 2027: Potential regulatory approval expected for Helios ARDS product in Japan.
  • Geopolitical/Business Context: SABbio views Japan as the strategic launchpad for cell therapy due to regulatory support and cost advantages before targeting the larger US market.